Keywords: Antineoplastic Agent, Formylpeptide Receptor Like 1, Serylarginylserylarginyltyrosine, Unclassified Drug, Urokinase Receptor, Animal Cell, Antineoplastic Activity, Article, Binding Affinity, Binding Site, Cell Function, Cell Motility, Concentration Response, Controlled Study, Cyclization, Drug Determination, Drug Effect, Drug Mechanism, Drug Protein Binding, High Performance Liquid Chromatography, Human, Human Cell, Migration Inhibition, Molecular Dynamics, Monocyte, Nonhuman, Protein Determination, Protein Function, Sequence Analysis, Mammalia, Rattus,
Affiliations: *** IBB - CNR ***
Department of Pharmacy, University Federico II, Naples, Italy
Neoplastic Progression Unit, Department of Experimental Oncology, IRCCS Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy
SUN Second University of Naples, Italy
University 'Parthenope', Naples, Italy
CIRPEB: Centro Interuniversitario di Ricerca Sui Peptidi Bioattivi University of Naples Federico II, DFM-Scarl, Institute of Biostructures and Bioimaging - CNR, Naples, Italy
References: Not available.
Cyclization of the urokinase receptor-derived Ser-Arg-Ser-Arg-Tyr peptide generates a potent inhibitor of trans-endothelial migration of monocytes
Petraglia F, Singh AA, Carafa V, Nebbioso A, Conte M, Scisciola L, Valente S, Baldi A, Mandoli A, Petrizzi VB, Ingenito C, De Falco S, Cicatiello V, Apicella I, Janssen-megens EM, Kim B, Yi G, Logie C, Heath S, Ruvo M, Wierenga ATJ, Flicek P, Yaspo ML, Della Valle V, Bernard O, Tomassi S, Novellino E, Feoli A, Sbardella G, Gut I, Vellenga E, Stunnenberg HG, Mai A, Martens JHA, Altucci L * Combined HAT/EZH2 modulation leads to cancer-selective cell death(450 views) Oncotarget (ISSN: 1949-2553electronic, 1949-2553linking), 2018 May 22; 9(39): 25630-25646. Impact Factor:5.008 ViewExport to BibTeXExport to EndNote